RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC.
IEX Last Trade
1.835
0.085 4.632%
Share volume: 18,012
Last Updated: Fri 27 Dec 2024 08:30:29 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$1.75
0.09
4.86%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
13.41%
1 Month
63.16%
3 Months
37.78%
6 Months
45.31%
1 Year
-63.81%
2 Year
-42.06%
Key data
Stock price
$1.84
DAY RANGE
$1.73 - $1.92
52 WEEK RANGE
$0.69 - $5.67
52 WEEK CHANGE
-$63.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Laxminarayan Bhat
Region: US
Website: revivapharma.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: revivapharma.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.
Recent news